{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:22:10Z","timestamp":1794057730642,"version":"4.8.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T00:00:00Z","timestamp":1642809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T00:00:00Z","timestamp":1642809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40264-021-01138-z","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T15:02:18Z","timestamp":1642863738000},"page":"137-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3769-1346","authenticated-orcid":false,"given":"Robin E.","family":"Ferner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-4060","authenticated-orcid":false,"given":"Richard J.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8793-6607","authenticated-orcid":false,"given":"Christopher","family":"Anton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-655X","authenticated-orcid":false,"given":"Jeffrey K.","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,22]]},"reference":[{"issue":"27","key":"1138_CR1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603\u201315.","journal-title":"N Engl J Med"},{"issue":"10269","key":"1138_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99\u2013111.","journal-title":"Lancet"},{"key":"1138_CR3","volume-title":"Statistics with confidence","author":"RG Newcombe","year":"2000","unstructured":"Newcombe RG, Altman DG. Chapter 6. Proportions and their differences. In: Altman DG, Machin D, Bryant TN, Gardner MJ, editors. Statistics with confidence. 2nd ed. London: BMJ Books; 2000.","edition":"2"},{"key":"1138_CR4","volume-title":"Guidelines for preparing core clinical-safety information on drugs","author":"Council for International Organizations of Medical Sciences","year":"1999","unstructured":"Council for International Organizations of Medical Sciences. Guidelines for preparing core clinical-safety information on drugs. 2nd ed. Geneva: CIOMS; 1999.","edition":"2"},{"key":"1138_CR5","volume-title":"Iatrogenic diseases","author":"JCP Weber","year":"1986","unstructured":"Weber JCP. Mathematical models in adverse drug reaction assessment. In: D\u2019Arcy PF, Griffin JP, editors. Iatrogenic diseases. 3rd ed. Oxford: Oxford University Press; 1986.","edition":"3"},{"key":"1138_CR6","unstructured":"European Medicines Agency. COVID-19 Vaccine AstraZeneca: PRAC preliminary view suggests no specific issue with batch used in Austria. London: EMA. https:\/\/www.ema.europa.eu\/en\/news\/covid-19-vaccine-astrazeneca-prac-preliminary-view-suggests-no-specific-issue-batch-used-austria. Accessed 5 June 2021."},{"key":"1138_CR7","unstructured":"BBC News. Oxford-AstraZeneca: EU says \u2018no indication\u2019 vaccine linked to clots. https:\/\/www.bbc.co.uk\/news\/world-europe-56357760. Accessed 5 June 2021."},{"key":"1138_CR8","unstructured":"British Society for Haematology. Guidance produced by the Expert Haematology Panel Focussed on Vaccine Induced Thrombosis and Thrombocytopenia (VITT). https:\/\/b-s-h.org.uk\/about-us\/news\/guidance-produced-by-the-expert-haematology-panel-ehp-focussed-on-vaccine-induced-thrombosis-and-thrombocytopenia-vitt\/. Accessed 3 Nov\u00a02021."},{"issue":"23","key":"1138_CR9","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","volume":"384","author":"M Scully","year":"2021","unstructured":"Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384(23):2202\u201311. https:\/\/doi.org\/10.1056\/NEJMoa2105385.","journal-title":"N Engl J Med"},{"issue":"22","key":"1138_CR10","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092\u2013101.","journal-title":"N Engl J Med"},{"issue":"3","key":"1138_CR11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s11239-021-02484-6","volume":"52","author":"MMJ Bauman","year":"2021","unstructured":"Bauman MMJ, Naylor RM, Wijdicks EF. HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia. J Thromb Thrombolysis. 2021;52(3):952\u201361. https:\/\/doi.org\/10.1007\/s11239-021-02484-6.","journal-title":"J Thromb Thrombolysis"},{"key":"1138_CR12","unstructured":"Medicines & Healthcare products Regulatory Agency. Research and analysis. Coronavirus vaccine\u2014weekly summary of Yellow Card reporting. https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting. Accessed 3 Nov 2021."},{"issue":"3","key":"1138_CR13","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/S0161-6420(02)01766-9","volume":"110","author":"QD Nguyen","year":"2003","unstructured":"Nguyen QD, Van Do D, Feke GT, Demirjian ZN, Lashkari K. Heparin-induced antiheparin-platelet antibody associated with retinal venous thrombosis. Ophthalmology. 2003;110(3):600\u20133.","journal-title":"Ophthalmology"},{"key":"1138_CR14","unstructured":"European Centre for Disease Prevention and Control. COVID-19 Vaccine rollout review. https:\/\/covid19-vaccine-report.ecdc.europa.eu\/. Accessed 6 Nov 2021."},{"key":"1138_CR15","unstructured":"European Union. Size and population. 2021.\u00a0https:\/\/europa.eu\/european-union\/about-eu\/figures\/living_en#size-and-population. Accessed 6 Nov 2021."},{"key":"1138_CR16","unstructured":"Worldometer. Countries in the world by population. 2021. https:\/\/www.worldometers.info\/world-population\/population-by-country\/. Accessed 3 Nov 2021."},{"key":"1138_CR17","unstructured":"Medicines & Healthcare products Regulatory Agency. COVID-19 AstraZeneca Vaccine Analysis Print. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/989997\/COVID-19_vaccine_AstraZeneca_analysis_print.pdf. Accessed 5 June 2021."},{"key":"1138_CR18","unstructured":"Medicines & Healthcare products Regulatory Agency. COVID-19 mRNA Pfizer-BioNTech Vaccine Analysis Print. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/989996\/COVID-19_mRNA_Pfizer-_BioNTech_Vaccine_Analysis_Print.pdf. Accessed 3 Nov 2021."},{"key":"1138_CR19","unstructured":"The Medical Dictionary for Regulatory Activities (MedDRA). https:\/\/www.meddra.org\/about-meddra\/organisation. Accessed 12 June 2021."},{"issue":"2","key":"1138_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","volume":"32","author":"M Hauben","year":"2009","unstructured":"Hauben M, Aronson JK. Defining \u2018signal\u2019 and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 2009;32(2):99\u2013110.","journal-title":"Drug Saf"},{"key":"1138_CR21","unstructured":"YellowCard Interactive Drug Analysis Profiles. https:\/\/yellowcard.mhra.gov.uk\/iDAP\/. Accessed 3 Nov\u00a02021."},{"key":"1138_CR22","unstructured":"Eudravigilance \u2013 European database of suspected adverse drug reaction reports. https:\/\/www.adrreports.eu\/en\/. Accessed 6 Nov 2021."},{"key":"1138_CR23","unstructured":"de La Mare T. Five countries halt use of one batch of AstraZeneca jab after fatal blood clot. Evening Standard 2021 Mar 10. https:\/\/www.standard.co.uk\/news\/uk\/astrazeneca-austria-latvia-luxembourg-lithuania-b923420.html. Accessed 18 Jan\u00a02022."},{"issue":"5958","key":"1138_CR24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/bmj.1.5958.595","volume":"1","author":"P Wright","year":"1975","unstructured":"Wright P. Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J. 1975;1(5958):595\u20138.","journal-title":"Br Med J"},{"key":"1138_CR25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2125.2005.02527.x","volume":"61","author":"RM Martin","year":"2006","unstructured":"Martin RM, May M, Gunnell D. Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001\u20132004. Br J Clin Pharmacol. 2006;61:224\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1138_CR26","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1111\/bcp.14563","volume":"87","author":"LGM Postma","year":"2021","unstructured":"Postma LGM, Donyai P. The cooccurrence of heightened media attention and adverse drug reaction reports for hormonal contraception in the United Kingdom between 2014 and 2017. Br J Clin Pharmacol. 2021;87(4):1768\u201377.","journal-title":"Br J Clin Pharmacol"},{"issue":"5918","key":"1138_CR27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/bmj.2.5918.560","volume":"2","author":"P Wright","year":"1974","unstructured":"Wright P. Skin reactions to practolol. Br Med J. 1974;2(5918):560.","journal-title":"Br Med J"},{"issue":"10","key":"1138_CR28","first-page":"949","volume":"34","author":"N Iessa","year":"2011","unstructured":"Iessa N, Star K, Wilton L, Curran S, Edwards IR, Aronson JK, Murray M, Besag FM, Wong IC. Montelukast and suicide: causality assessment using spontaneous reports and Bradford Hill guidelines. Drug Saf. 2011;34(10):949\u201350.","journal-title":"Drug Saf"},{"issue":"1","key":"1138_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaip.2020.07.052","volume":"9","author":"V Sansing-Foster","year":"2021","unstructured":"Sansing-Foster V, Haug N, Mosholder A, et al. Risk of psychiatric adverse events among montelukast users. J Allergy Clin Immunol Pract. 2021;9(1):385-393.e12.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1138_CR30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00002018-200831060-00006","volume":"31","author":"J de Langen","year":"2008","unstructured":"de Langen J, van Hunsel F, Passier A, et al. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf. 2008;31:515\u201324.","journal-title":"Drug Saf"},{"issue":"20","key":"1138_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta15200","volume":"15","author":"AJ Avery","year":"2011","unstructured":"Avery AJ, Anderson C, Bond CM, et al. Evaluation of patient reporting of adverse drug reactions to the UK \u201cYellow Card Scheme\u201d: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1\u2013234, iii\u2013iv.","journal-title":"Health Technol Assess"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01138-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01138-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01138-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T13:30:35Z","timestamp":1645191035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01138-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,22]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1138"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01138-z","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,22]]},"assertion":[{"value":"8 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to assist in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors have completed the ICMJE uniform disclosure form. JKA and REF have both written widely about adverse drug reactions and interactions and have from time to time received fees for legal reports, payments for articles, and royalties on books that they have written on the subject. The West Midlands Centre for Adverse Drug Reactions is associated with the Yellow Card Centre West Midlands, which receives funds from the MHRA. CA has no other conflicts of interest relevant to this article. RS is a member of the Central Advisory Committee, and an Electronic Review Committee, which advise the MHRA on governance of the Clinical Practice Research Datalink; the views expressed here do not reflect that role or that of the MHRA. All authors assert that the views expressed in this article are their own and do not necessarily reflect those of any organization with which they may be associated.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Publicly available data were used for this research.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the design of the study and the analysis of the results. CA and REF retrieved the data for the study. REF wrote the first draft of the manuscript. RS constructed the graphs. All authors contributed to manuscript revision and read and approved the submitted version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}